Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis (PARCS)

Assistance Publique - Hôpitaux de Paris

Status: Completed

Conditions: Sarcoidosis

Treatments: Radiation: Rubidium PET

Study type: Interventional

Funder types: Other

Identifiers

NCT01648933

AOR10027

Details and patient eligibility

About

The study aims at assessing diagnostic and therapeutic impact of Rubidium-82 PET in cardiac sarcoidosis.

Full description

The presence of cardiac involvement is a serious complication of sarcoidosis. Early diagnosis is challenging since it relies on an array of clinical, biological and imaging abnormalities. Myocardial perfusion imaging with sestamibi is currently a major feature of the diagnosis, since it allows to evidence both microcirculatory impairments and scar. However, some technical limitations are inherent to SPECT, mainly poor spatial resolution and lack of attenuation correction, resulting in the absence of flow quantification. Rubidium-82 (Rb) PET proved to be more sensitive and specific than sestamibi SPECT in the diagnosis of coronary artery disease. Furthermore, it allows noninvasive measurement of coronary flow reserve. Finally, it exposes patients to lower radiation dose than SPECT. Therefore, Rb PET may help to better identify cardiac involvement of sarcoidosis, and hence to better select those patients who require high-dose steroids.

Enrollment: 53 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• (1) histologically proven sarcoidosis;
• (2) suspicion of cardiac involvement on symptoms, and/or ECG and/or echocardiogram.

Exclusion criteria

• patient < 18 years old

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

53 participants in 1 patient group

Sarcoidosis

Experimental group

Description:

Rubidium PET: Myocardial Perfusion Imaging

Treatment:

Radiation: Rubidium PET